Eliška Šranková
Junior Researcher, Research Specialist
Medicinal Chemistry
Our team investigates fundamental mechanisms and translates findings from bench to bedside, combining preclinical models with clinical insight.
Researcher at ICRC with focus on translational medicine. Combines preclinical insights with clinical practice across cardiology, neurology, and oncology programs.
Currently leads / contributes to interdisciplinary projects bridging molecular biology, imaging, and patient care at St. Anne's University Hospital Brno.
Research Group
- Team size
- Team size: 8 Researchers
- Place
- Place: Building D3, Ground Floor
- Collaborates with
- Collaborates with MUNI Clinic
Head of Research Group
- doc. Mgr. Kamil Paruch, Ph.D.
Members
Mgr. Gabriela Pavlíková
Research Assistant, Senior Research Coordinator
Prashantkumar Dineshbhai Khirsariya, Ph.D., MSc
Postdoctoral Researcher, Senior Research Specialist
RNDr. Marek Remeš, Ph.D.
Postdoctoral Researcher
doc. Mgr. Kamil Paruch, Ph.D.
Principal Investigator, Senior Research Team Leader
Mgr. Lukáš Maier, Ph.D.
Senior Postdoctoral Researcher
Mgr. Jakub Švenda, Ph.D.
Head Researcher
Mgr. Štěpán Havel
Research Specialist
Team Assistant
Mgr. Gabriela Pavlíková
Administrative Support
Main Objectives
- Total synthesis of new analogs of forskolin and testing their activity against human adenylyl cyclases.
- dentification of new inhibitors targeting underexplored protein kinases.
- SAR development around the existing proprietary inhibitors of nucleases MRE11 and Mus81; identification of sub-micromolar inhibitors.
- Synthesis and biological profiling of new carbocyclic C-nucleosides.
Research focus
The research in our laboratory focuses on development of synthetic methods and strategies for preparation of structurally non-trivial small molecules for applications in biomedical research. Specifically, our project includes:
Development of potent inhibitors of certain „non-routine“ kinases (CLK, HIPK).
Synthesis of new forskolin-based modulators of adenylyl cyclases
Identification inhibitors of selected DNA repair pathways (nucleases Mre11 and Mus81).
Preparation of new small-molecules probes of cell differentiation, and fluorescent probes for biological systems.
Organic synthesis of small-molecule organic compounds of medium complexity.
Medicinal chemistry – optimization of early leads.
Technological equipment
- HPLC with UV, MS and CAD detection
- NMR spectrometer
- microwave reactor
- high pressure reactor
- automatic purification systems
Selected Results
- Khirsariya, P.; Pospíšil, P.; Maier, L.; Boudný, M.; Babáš, M.; Kroutil, O.; Mráz, M.; Vácha, R.; Paruch, K. Synthesis and profiling of highly selective inhibitors of methyltransferase DOT1L based on carbocyclic C-nucleosides. J. Med. Chem. 2022, 65, 5701.
- Tharra, P. R.; Mikhaylov, A.; Švejkar, J.; Gysin, M.; Hobbie, S. N.; Švenda, J. Short synthesis of (+)-actinobolin: Simple entry to complex small-molecule inhibitors of protein synthesis. Angew. Chem. Int. Ed. 2022, 61, e202116520.
- Němec, V.; Maier, L.; Berger, B.-T.; Chaikuad, A.; Drápela, S.; Souček, K.; Knapp, S.; Paruch, K. Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core. Eur. J. Med. Chem. 2021, 215, 113299.
- Vojáčková, P.; Michalska, L.; Nečas, M.; Shcherbakov, D.; Bottger, E. C.; Šponer, J.; Šponer, J.; Švenda, J. Stereocontrolled Synthesis of (−)-Bactobolin A. J. Am. Chem. Soc. 2020, 142, 7306.
- Boudný, M.; Zemanová, J.; Khirsariya, P.; Borský, M.; Verner, J.; Černá, J.; Oltová, A.; Šeda, V.; Mráz, M.; Jaroš, J.; Kašparková, M.; Jašková, Z.; Spunarová, M.; Brychtová, Y.; Souček, K.; Drápela, S.; Mayer, J.; Paruch, K.; Trbušek, M. Novel Chk1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica 2019, 104, 2443.
- Němec, V.; Hylsová, M.; Maier, L.; Flegel, J.; Sievers, S.; Ziegler, S.; Schröder, M. Berger, B.-T.; Chaikuad, A.; Valčíková, B.; Uldrijan, S.; Drápela, S.; Souček, K.; Waldmann, H.; Knapp, S.; Paruch, K. Furo[3,2-b]pyridine: A novel privileged scaffold for highly selective kinase inhibitors and effective modulators of the Hedgehog pathway. Angew. Chem. Int. Ed. 2019, 58, 1062.
